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Abstract
Background: Systemic sclerosis (SSc) is characterized by early vascular abnormalities and subsequent fibroblast
activation to myofibroblasts, leading to fibrosis. Recently, endothelial-to-mesenchymal transition (EndoMT), a
complex biological process in which endothelial cells lose their specific markers and acquire a mesenchymal or
myofibroblastic phenotype, has been reported in SSc. In the present study, we evaluated the ability of endothelin-1
(ET-1) dual receptor antagonists bosentan (BOS) and macitentan (MAC) to antagonize EndoMT in vitro.
Methods: Ten women with limited SSc were enrolled. They underwent double skin biopsy (affected and nonaffected
skin). Fibroblasts and microvascular endothelial cells (MVECs) were isolated from biopsies. We performed mono- or
coculture of MVECs (isolated from nonaffected skin) with fibroblasts (isolated from affected skin and stimulated
with ET-1 and transforming growth factor beta [TGF-β]). In cocultures, the MVEC layer was left undisturbed or was
preincubated with BOS or MAC. After 48 h of coculture, MVECs were analyzed for their tube formation ability and
for messenger RNA and protein expression of different vascular (CD31, vascular endothelial growth factor-A [VEGF-A],
VEGF-A165b) and profibrotic (alpha-smooth muscle actin [α-SMA], collagen type I [Col I], TGF-β) molecules.
Results: After 48 h, MVECs showed a reduced tube formation ability when cocultured with SSc fibroblasts. CD31
and VEGF-A resulted in downregulation, while VEGF-A165b, the antiangiogenic isoform, resulted in upregulation.
At the same time, mesenchymal markers α-SMA, Col I, and TGF-β resulted in overexpression in MVECs. Tube formation
ability was restored when MVECs were preincubated with BOS or MAC, also reducing the expression of mesenchymal
markers and restoring CD31 expression and the imbalance between VEGF-A and VEGF-A165b.
Conclusions: With this innovative EndoMT in vitro model realized by coculturing nonaffected MVECs with affected SSc
fibroblasts, we show that the presence of a myofibroblast phenotype in the fibroblast layer, coupled with an ET-1-TGF-β
synergic effect, is responsible for EndoMT. BOS and MAC seem able to antagonize this phenomenon in vitro, confirming
previous evidence of endothelium-derived fibrosis in SSc and possible pharmacological interference.
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Background
Systemic sclerosis (SSc) is an autoimmune connective
tissue disease characterized by cutaneous and visceral
fibrosis coupled with widespread vascular pathology [1].
The first sign occurring in 90–98 % of patients with
SSc is Raynaud’s phenomenon, an abnormal reactivity
of digital microvasculature under cold and other stimuli
[2, 3], which highlights the central role of microvascu-
lar damage in the pathogenesis of SSc [4]. In SSc, im-
balance of endothelial signals, such as increased release
of vasoconstrictory endothelin 1 (ET-1), thromboxane,
and thrombomodulin, and reduction of prostaglandin
I2 and nitric oxide are signs of the endothelial injury
[5]. Although different molecules have been identified
as key effectors of vascular remodeling in SSc, such as
ET-1 and transforming growth factor beta (TGF-β), the
mechanisms underlying SSc vasculopathy remain poorly
understood [6]. There are two important issues: how
the vascular damage can lead to the fibrotic process
and the relationship between vessel disappearance and
myofibroblast activation [7]. In fact, myofibroblasts in
fibrotic tissues are derived from at least three sources:
expansion and activation of resident tissue fibroblasts, tran-
sition of epithelial cells into mesenchymal cells (epithelial-
to-mesenchymal transition [EMT]), and tissue migration of
bone marrow-derived circulating fibrocytes [8]. Recently,
endothelial-to-mesenchymal transition (EndoMT), a newly
recognized type of cellular transdifferentiation, has emerged
as another possible source of tissue myofibroblasts [9].
EndoMT is a complex biological process in which endo-
thelial cells lose their specific markers and acquire a
mesenchymal or myofibroblastic phenotype and express
mesenchymal cell products such as alpha smooth muscle
actin (α-SMA) and collagen type I (Col I) [8, 9]. Despite
evidence suggesting that EndoMT is involved in not only
pathological [10–12] but also physiological conditions
[13], the underlying molecular mechanisms involved in
this process are largely unknown. Similarly to EMT,
EndoMT can be induced by TGF-β [14]. Of note, the
same molecule is considered, together with ET-1, to be
a pivotal player in the developmental of SSc fibrosis
[15]. It is well documented that the activation of TGF-β
intracellular transcription factors is responsible of the
production of other fibrotic molecules, such as ET-1
[16]. Moreover, TGF-β-induced ET-1 release has been
associated with the fibrotic response of skin and lung SSc
fibroblasts [17]. In the present study, we established an in
vitro model of EndoMT made up of fibroblast and micro-
vascular endothelial cell (MVEC) cocultures. Considering
the synergistic action of ET-1 and TGF-β to induce
EndoMT, we investigated the potential of ET-1 dual recep-
tor antagonists bosentan (BOS) and macitentan (MAC) to
antagonize EndoMT in our in vitro coculture model.
Methods
Patient enrollment, skin biopsy, and cell isolation
Patients
We enrolled ten women (age 55.7 ± 12.3 years, disease
duration 8.3 ± 1.8 years) affected by limited SSc (lSSc)
in accordance with the description of LeRoy and col-
leagues [18] and who fulfilled the 2013 American College
of Rheumatology/European League Against Rheumatism
diagnostic criteria for SSc [19]. Table 1 shows the major
demographic and clinical characteristics of these patients.
We performed skin biopsies by using a 3-mm punch on
affected skin graded as 2 according to modified Rodnan
skin score (mRSS) [20]. Unaffected areas of midforearm
skin from the same patients with lSSc were also taken.
The unaffected skin of patients with lSSc was defined by
clinical palpation (graded as 0 according to mRSS) and by
histological examination that excluded SSc-related lesions.
Table 1 Clinical parameters of patients with limited systemic sclerosis
Patient Age (years) Sex Disease duration (years) Digital ulcers PAH mRSS/score at affected skin biopsy ANA-ENA
1 64 F 8 no no 10/2 Anticentromere-CenpB
2 35 F 9 no no 09/2 Anticentromere-CenpB
3 72 F 11 yes yes 13/2 Anticentromere-CenpB
4 49 F 7 no no 10/2 Anticentromere-CenpB
5 37 F 5 no no 10/2 Anticentromere-CenpB
6 52 F 10 no no 11/2 Anticentromere-CenpB
7 59 F 8 yes yes 13/2 Anticentromere-CenpB
8 66 F 9 no no 09/2 Anticentromere-CenpB
9 58 F 6 no no 10/2 Anticentromere-CenpB
10 65 F 10 no no 10/2 Anticentromere-CenpB
Mean (SD) 55.7 (12.3) 8.3 (1.8)
Abbreviations: ANA Antinuclear antibodies, ENA Extractable nuclear antigens, CenpB Centromere protein B, mRSS Modified Rodnan skin score, PAH Pulmonary
arterial hypertension
Patients discontinued corticosteroids, oral vasodilators, intravenous prostanoids, and other disease-modifying drugs at least 1 month before skin biopsies
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Fibroblast isolation and cultures
Fibroblasts were isolated from skin specimens by enzymatic
digestion. Briefly, explants were de-epidermized using a dis-
pase solution (dispase activity 14 U/ml; Sigma-Aldrich, St.
Louis, MO, USA) for 2 h at 37 °C and then were dissolved
into a collagenase III solution (2.4 U/ml; Sigma-Aldrich) for
30 minutes. Fibroblasts obtained were passaged twice and
cultured at a density of 1 × 106 cells per flask in DMEM
(Sigma-Aldrich) supplemented with penicillin (100 U/ml;
Sigma-Aldrich), streptomycin (100 μg/ml; Sigma-Aldrich),
amphotericin B (0.25 μg/ml; Sigma-Aldrich), glutamine
(2 mM; Sigma-Aldrich), and 10 % FBS (Sigma-Aldrich),
followed by incubation at 37 °C in an atmosphere of 5 %
CO2 and 95 % air until confluence (1 week) in 75-cm
2
flasks (BD Costar, Cambridge, MA, USA). Viability was
estimated by trypan blue staining (Sigma-Aldrich).
Fibroblasts were used at third passage (P3) for cocultures.
MVEC isolation and cultures
Biopsy samples were washed with PBS (Sigma-Aldrich)
and placed into a 50-ml tube (BD Costar) containing
15 ml of trypsin (Sigma-Aldrich) for digestion at 37 °C for
45 minutes. Cells were cultured in EGM-MV microvascu-
lar endothelial cell growth medium (Lonza, Walkersville,
MD, USA) at 37 °C in an atmosphere of 5 % CO2 and
95 % air. Before reaching confluence, the heterogeneous
pool of cells was exposed to a cluster of differentiation 31
(CD31)-positive selection by using the DynaBeads mag-
netic CD31 MicroBeads cell-sorting system (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s instruc-
tions. After removing CD31-negative cells, only cells posi-
tive for CD31 were collected. MVECs obtained were used
at P3 for mono- and cocultures.
EndoMT coculture model
In order to set up an in vitro model of EndoMT, fibro-
blasts isolated from affected skin biopsies and MVECs
isolated from unaffected skin areas were cocultured in
Transwell® 12-well plate inserts (0.4-μm pore size; Corning,
Corning, NY, USA). Fibroblasts and MVECs were seeded
in cocultures in a 1:3 ratio: fibroblasts in transwell inserts
and MVECs in the bottom of the wells. The following
cocultures of affected fibroblasts with affected MVECs
(positive control) and unaffected fibroblasts with un-
affected MVECs (negative control) were also performed.
The fibroblast layer of the EndoMT model was incubated
with 100 nM ET-1 and 5 ng/ml TGF-β for 48 h to perman-
ently maintain the myofibroblast phenotype in culture. The
MVEC layer of the EndoMT model was left undisturbed
for 48 h or preincubated with 10 μM BOS or 1 μM MAC
[6] 1 h before treating the fibroblast layer with ET-1 and
TGF-β.
Tube formation ability of MVECs
Tube formation ability was evaluated using a Matrigel
assay. Matrigel (BD Biosciences, San Jose, CA, USA) was
used at 8.6 mg/ml in a 1:1 dilution with EGM2-MV
(Lonza), without any supplement. MVECs were labeled,
before coculture in Matrigel, with the red fluorescent
dye PKH26 (Sigma-Aldrich) following the manufacturer’s
instructions. After 48 h of mono- or coculture with fibro-
blasts, MVECs tube total length in each well, calculated as
cells per millimeter, were calculated by using a Zeiss
AxioPlan2 fluorescence microscope equipped with AxioVi-
sion 4.6 for Windows software (Carl Zeiss Vision GmbH,
Hallbergmoos, Germany). The number of branching points
was calculated using MetaMorph® software for Windows
(Molecular Devices, Sunnyvale, CA, USA). The number of
tubes formed was quantitated by an observer blinded to
the experimental groups.
Western blot analysis
Collected MVECs were centrifuged at 1500 rpm for 10 mi-
nutes at room temperature. Pellets were then suspended
in PBS buffer and centrifuged at 3000 rpm for 20 minutes
at 4 °C. The obtained pellets were then suspended in
radioimmunoprecipitation assay buffer (Sigma-Aldrich)
containing protease inhibitor cocktail (Sigma-Aldrich)
for 40 minutes in ice and then centrifuged at 15000 rpm
for 30 minutes at 4 °C. After centrifugation, supernatants
were collected, and protein concentration was calculated
according to Bradford assay [21]. About 20 μg of cell lys-
ate proteins for each lane were resolved in a 12 % SDS-
PAGE buffer according to Laemmli [22]. The bands were
transferred from the gels to polyvinyl difluoride mem-
branes using the iBlot™ Dry Blotting System (Invitrogen).
The endothelial markers chosen for MVECs were rabbit
polyclonal anti-CD31 (Abcam, Cambridge, UK), rabbit
polyclonal anti-vascular endothelial growth factor A (anti-
VEGF-A) (Abcam), and rabbit polyclonal anti-VEGF-
A165b (Abcam). The mesenchymal markers chosen for
MVECs were rabbit polyclonal anti-α-SMA (Abcam),
rabbit polyclonal anti-Col-I (Abcam), and rabbit poly-
clonal anti-TGF-β (Abcam). Incubation was carried out
using iBlot® Western Detection Kit (Invitrogen). The load
control protein used was beta actin (Abcam). The bound
primary antibodies were detected using antirabbit im-
munoglobulin G alkaline phosphate conjugate (Invitrogen)
and visualized using a ChemiDoc™ XRS 170-870 molecu-
lar imager (Bio-Rad Laboratories, Hercules, CA, USA)
and quantified by using Quantity One software (Bio-Rad
Laboratories).
RNA isolation and quantitative real-time polymerase
chain reaction
MVECs were collected in TRIzol reagent (Sigma-Aldrich).
Total RNA was extracted following the manufacturer’s
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instructions. The total RNA content of the samples was
quantified by measuring the absorbance at 260 nm using
an Ultrospec 2000 spectrophotometer (Amersham
Pharmacia Biotech, Piscataway, NJ, USA). The RNA was
then reverse-transcribed using a random hexamer
MultiScribe enzyme (Applied Biosystems, Foster City,
CA, USA). Quantitative real-time polymerase chain reac-
tions (qRT-PCR) were run in the StepOne Real-Time PCR
System (Applied Biosystems) using TaqMan chemistry
(Invitrogen). Two microliters of complementary DNA in a
final volume of 20 μl were amplified using the 20×
Assays-on-Demand gene expression assay mix (Applied
Biosystems). Specific primers were designed on the
basis of the reported sequences (National Center for Bio-
technology Information PrimerBank): α-SMA: 5′-CGGT
GCTGTCTCTCTATGCC-3′ (forward) and 5′-CGCTCA
GTCAGGATCTTCA-3′ (reverse); Col I: 5′-AGGGCCAA
GACGAAGACAGT-3′ (forward) and 5′-AGATCACGTC
ATCGCACAACA-3′ (reverse); TGF-β: 5′-CTAATGGTG
GAAACCCACAACG-3′ (forward) and 5′-TATCGCCAG
GAATTGTTGCTG-3′ (reverse); CD31: 5′-AACAGTGT
TGACATGAAGAGCC-3′ (forward) and 5′-TGTAAAA-
CAGCACGTCATCCTT-3′ (reverse); VEGF-A: 5′-AGGG
CAGAATCATCACGAAGT-3′ (forward) and 5′-GCTGC
GCTGATAGACATCCA-3′ (reverse); VEGF-A165b: 5′-G
AGCAAGACAAGAAAATCCC-3′ (forward) and 5′-
GTGAGAGATCTGCAAGTACG-3′ (reverse). TaqMan
probes, specific primers and ribosomal 18S, selected as
a housekeeping gene, were purchased from Applied
Biosystems. Messenger RNA (mRNA) levels were normal-
ized to those of 18S.
Statistical analysis
Prism 6.0® for Windows software (GraphPad Software,
La Jolla, CA, USA) was used for statistical analysis. Data
regarding Western blot analyses are expressed as mean ±
SD of three technical replicates evaluated by analysis of
variance (ANOVA) and Tukey’s multiple-comparisons test.
Significance was set at p < 0.05. Data related to the number
of branching points are expressed as mean ± SD, while
those related to tube formation ability and to qRT-PCR are
expressed as median (range) of six biological replicates. Be-
cause the data followed a nonparametric distribution, the
Mann-Whitney U test was thought to be appropriate for
the analyses. Significance was set at p < 0.05.
Results
Tube formation ability of MVECs
In our in vitro EndoMT model, MVECs cocultured with
affected fibroblasts (stimulated with ET-1 and TGF-β)
showed a significant impairment in tube formation, prob-
ably due to the persistent stimulation of the myofibroblast
phenotype (Fig. 1a). After 48 h of coculture, MVECs sta-
tistically reduced their ability to form tubular structures
in untreated samples. In fact, as shown in Fig. 1b, the
analysis of tube formation ratio evidenced significant
improvement in tube formation when MVECs were
preincubated with BOS (p < 0.01) and MAC (p < 0.01).
Fig. 1 a Tubular structure formation of microvascular endothelial cells (MVECs) in Matrigel after 48 h of culture alone (before endothelial-to-mesenchymal
transition [EndoMT]) or cocultures with fibroblasts. The fluorescent red images show that MVECs (post-EndoMT) have a decreased tube formation ability
with respect to those treated with bosentan (BOS) and macitentan (MAC), which show a well-organized tubelike network. b The tube formation ability
was measured as cells per millimeter and is expressed as the ratio of total tube length in each culture condition to the length in the culture
of untreated (CTR) MVECs. Data are expressed as median (range) of six biological replicates (*p < 0.05, **p < 0.01). c Number of branching
points expressed as mean ± SD of six biological replicates (*p < 0.05)
Corallo et al. Arthritis Research & Therapy  (2016) 18:228 Page 4 of 9
These data were confirmed by analysis of the number
of branching points (Fig. 1c) that were statistically in-
creased when MVECs were incubated with BOS (p < 0.05)
and MAC (p < 0.05).
Effect of BOS and MAC on endothelial marker expression
in MVECs
As shown in Fig. 2, both BOS and MAC are able to
antagonize the EndoMT process after 48 h. In particular,
1 h of preincubation with 10 μM BOS led to both
protein (p < 0.01) and mRNA (p < 0.01) increases of
CD31, and also of both protein (p < 0.01) and mRNA
(p < 0.05) increases of VEGF-A. At the same time, the
antiangiogenic VEGF-A165b protein (p < 0.01) but not
mRNA levels statistically decreased. Conversely, 1 h of
preincubation with 1 μM MAC led to both protein (p <
0.01) and mRNA (p < 0.01) increases of CD31, and also of
both protein (p < 0.01) and mRNA (p < 0.01) increases
of VEGF-A. VEGF-A165b protein (p < 0.01) and mRNA
(p < 0.05) levels statistically decreased.
Fig. 2 a Western blot analyses (left) and the relative densitometric values (right) of cluster of differentiation 31 (CD31), vascular endothelial growth
factor (VEGF)-A, and VEGF-A165b. Densitometric data are representative of three technical triplicates and are expressed as mean ± SD. The values
of protein synthesis obtained for each treatment (bosentan [BOS] and macitentan [MAC]) were normalized to that of the untreated cells (CTR)
taken as unit value by definition. Analysis of variance and Tukey’s multiple-comparisons test were performed for each group (*p < 0.05, **p < 0.01).
b Quantitative real-time polymerase chain reaction analyses for CD31 (top), VEGF-A (middle), and VEGF-A165b (bottom) confirm the results observed in
Western blot analysis. The results are expressed as median (range) of six biological replicates (*p < 0.05, **p < 0.01). mRNA Messenger RNA;
EndoMT Endothelial-to-mesenchymal transition
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Effect of BOS and MAC on mesenchymal marker
expression in MVECs
Figure 3 shows that BOS and MAC are able to antagonize
the EndoMT through the expression of typical mesenchy-
mal markers in MVECs. In particular, BOS is respon-
sible for both protein (p < 0.01) and mRNA (p < 0.05)
decreases of α-SMA, protein (p < 0.01) and mRNA
(p < 0.05) decreases of Col I, and protein (p < 0.01)
and mRNA (p < 0.05) decreases of TGF-β. MAC is re-
sponsible for both protein (p < 0.05) and mRNA (p < 0.05)
decreases of α-SMA, protein (p < 0.01) and mRNA (p <
0.01) decreases of Col-1, and protein (p < 0.05) and
mRNA (p < 0.01) decreases of TGF-β.
Discussion
The in vitro experimental model of EndoMT described
in the present study provides evidence that the persistence
of the myofibroblast phenotype in SSc and its mediators
(ET-1 and TGF-β) are responsible for the transdifferen-
tiation of MVECs toward the mesenchymal phenotype
[23, 24]. As reported in the literature, the onset of SSc
is represented mainly by vascular damage [4, 25], but
Fig. 3 a Western blot analyses (left) and the relative densitometric values (right) of alpha smooth muscle actin (α-SMA), collagen type I (Col I) and
transforming growth factor beta (TGF-β). Densitometric data are representative of three technical replicates and are expressed as mean ± SD. The
values of protein synthesis obtained for each treatment (bosentan [BOS] and macitentan [MAC]) were normalized to that of the untreated cells (CTR),
taken as unit value by definition. Analysis of variance and Tukey’s multiple-comparisons test were performed in each group (*p < 0.05, **p < 0.01).
b Quantitative real-time polymerase chain reaction analyses for α-SMA (top), Col I (middle), and TGF-β (bottom) confirm results obtained by
Western blot analysis. The results are expressed as median (range) of six biological replicates (*p < 0.05, **p < 0.01). mRNA Messenger RNA;
EndoMT Endothelial-to-mesenchymal transition
Corallo et al. Arthritis Research & Therapy  (2016) 18:228 Page 6 of 9
this EndoMT in vitro model could explain the persist-
ence of fibroblast-vascular crosstalk as a profibrotic
loop-promoting condition in SSc. In fact, the recruit-
ment of myofibroblasts in affected tissues, associated
with their elevated biosynthetic functions, may be consid-
ered as pivotal determinants of the extent and progression
rate of the fibrosis in SSc [26]. Using a tridimensional
Matrigel model, we showed the reduction of MVECs’
ability to form tubular structures when cocultured with
affected fibroblasts incubated with ET-1 and TGF-β. In
the same condition, it was possible to observe a switch
from proangiogenic to antiangiogenic VEGF isoforms,
as recently described in the literature [27, 28]. The overex-
pression of VEGF165b, an inhibitory splice variant of
VEGF, leads to insufficient angiogenesis in patients with
SSc [29]. Not only the VEGF family but also CD31, the
specific endothelial marker, seems to be downregulated
after 48 h of coculture during the EndoMT, a condition
recently described in the literature [30, 31]. MVECs lose
specific endothelial markers and increase mesenchymal
profibrotic markers, such as α-SMA, Col I, and TGF-β
[32]. This evidence allowed us to hypothesize that the
above-mentioned profibrotic switch may be considered a
normal response of MVECs in any physiological (wound
healing) [33] and pathological (SSc) [34] conditions char-
acterized by overexpression of ET-1 and TGF-β. In this
setting, considering the synergistic action of ET-1 and
TGF-β in triggering EndoMT [35], our study strengthens
the fundamental therapeutic utility that blocking the ET-1
system, by using dual endothelin-1 receptor antagonists
(ERA), could represent an important therapeutic strategy
[36]. Our in vitro model demonstrates that both BOS and
MAC are effective in inhibiting the ET-1/TGF-β-mediated
EndoMT, supporting the hypothesis that ET-1 may repre-
sent the ultimate mediator of TGF-β actions [37, 38]. It is
very important to highlight that not only MAC but also
BOS is effective in EndoMT antagonism in vitro. There-
fore, it could be hypothesized that the obtained results
depend more on ET-1 receptor (ETA and ETB) blocking
than on the physiochemical and pharmacokinetic prop-
erties of the ERA used, even though a functional in vitro
assay demonstrated that the potency of MAC is tenfold
higher than that of the parent compound BOS [39].
Translating these preclinical findings into clinical applica-
tions, we hypothesize that the therapeutic strategy of an-
tagonizing EndoMT could contribute to counteract
endothelial dysfunction in pulmonary arterial hyperten-
sion [40, 41], a frequent condition in patients with SSc
[42], and to counteract the steps leading to SSc digital ul-
cerations [43]. In fact, the remodeling effects of ERA on
microvascular damage progression in patients with SSc
who have undergone long-term treatment have already
been demonstrated by nailfold videocapillaroscopy and
laser Doppler analysis of fingertip blood flow [44–46].
Conclusions
The present study provides further in vitro evidence of the
use of ERA (BOS and MAC) in inhibiting the EndoMT
process, supporting the clinical efficacy of these drugs in
SSc therapy and their usefulness for interfering with pro-
gressive fibrosis.
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